復銳醫療科技(01696.HK)與國際醫美意見領袖達成戰略合作
格隆匯9月4日丨復銳醫療科技(01696.HK)宣佈,公司全資附屬公司,專注於能量源醫美設備美學解決方案提供商,AlmaLasersLtd.(「Alma」)與國際知名皮膚護理專家、企業家及醫美領域廣受認可的國際意見領袖JamieSherrill(「NurseJamie」)達成戰略合作。此次合作標誌着Alma在提高消費者互動,鞏固其高端美學技術領導地位的戰略部署中邁出重要一步。
公司相信,與JamieSherrill的合作將進一步提升消費者對Alma高端解決方案的認識,同時爲全球診所合作夥伴創造更強勁的需求並開拓新的增長機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.